➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Moodys
Johnson and Johnson
Colorcon
Merck
Baxter

Last Updated: June 15, 2021

DrugPatentWatch Database Preview

HEPARIN SODIUM Drug Profile


Email this page to a colleague

« Back to Dashboard

Which patents cover Heparin Sodium, and what generic alternatives are available?

Heparin Sodium is a drug marketed by Abraxis Pharm, Akorn, B Braun Medical Inc, Be Pharms, Casi Pharms Inc, Chamberlin Parenterl, Dell Labs, Dr Reddys, Fresenius Kabi Usa, Gland Pharma Ltd, Hikma, Hospira, Hospira Inc, Lilly, Luitpold, Mylan Labs Ltd, Nanjing King-friend, Organon Usa Inc, Parke Davis, Pfizer, Pharm Spec, Pharmacia And Upjohn, Sagent Pharms, Sandoz, Shenzhen Techdow, Smith And Nephew, Solopak, Watson Labs Inc, West-ward Pharms Int, Baxter Hlthcare, Mcgaw, B Braun, and Pharma Serve Ny. and is included in sixty-nine NDAs.

The generic ingredient in HEPARIN SODIUM is heparin sodium. There are seventy-seven drug master file entries for this compound. Sixteen suppliers are listed for this compound. Additional details are available on the heparin sodium profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Heparin Sodium

A generic version of HEPARIN SODIUM was approved as heparin sodium by HOSPIRA on April 28th, 1983.

  Get Started Free

Summary for HEPARIN SODIUM
Drug patent expirations by year for HEPARIN SODIUM
Drug Prices for HEPARIN SODIUM

See drug prices for HEPARIN SODIUM

Recent Clinical Trials for HEPARIN SODIUM

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Johns Hopkins UniversityPhase 4
The Third Xiangya Hospital of Central South UniversityPhase 3
Guangdong Provincial People's HospitalN/A

See all HEPARIN SODIUM clinical trials

Pharmacology for HEPARIN SODIUM

US Patents and Regulatory Information for HEPARIN SODIUM

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Organon Usa Inc HEPARIN SODIUM heparin sodium INJECTABLE;INJECTION 000552-010 Approved Prior to Jan 1, 1982 DISCN No No   Get Started Free   Get Started Free   Get Started Free
Smith And Nephew HEPARIN SODIUM heparin sodium INJECTABLE;INJECTION 088239-001 Jul 26, 1984 DISCN No No   Get Started Free   Get Started Free   Get Started Free
Fresenius Kabi Usa HEPARIN SODIUM heparin sodium INJECTABLE;INJECTION 017651-003 Approved Prior to Jan 1, 1982 DISCN No No   Get Started Free   Get Started Free   Get Started Free
Dr Reddys HEPARIN SODIUM heparin sodium INJECTABLE;INJECTION 017064-005 Approved Prior to Jan 1, 1982 DISCN No No   Get Started Free   Get Started Free   Get Started Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Moodys
Mallinckrodt
Johnson and Johnson
McKesson
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.